Trials / Withdrawn
WithdrawnNCT06078202
A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers
Assessment of the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Volunteers
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the relative bioavailability of three immediate-release table formulations of ABBV-903 under fasting conditions in healthy volunteers, and to evaluate the effect of food on the pharmacokinetics of three immediate-release table formulations of ABBV-903.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-903 | Tablet; oral |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2025-01-31
- Completion
- 2025-01-31
- First posted
- 2023-10-11
- Last updated
- 2024-09-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06078202. Inclusion in this directory is not an endorsement.